Kornimate/medical-research-clean huggingface dataset:
estimated cumulative incidence of zika infection at the end of the first epidemic in the french west indies in a sample of patients followed for hiv infection.

Conditions: HIV Infections; Zika Virus Infection

Summary: this study will estimate the cumulative incidence of zika infection at the end of the first epidemic in the french west indies in a sample of patients followed for hiv infection.

zika virus infection is expanding in all tropical and subtropical areas. the presence of aedes albopictus in southern france raises concerns about the occurrence of outbreaks of indigenous zika virus transmission. in this context, knowledge of the cumulative impact of the epidemic that affected the caribbean in 2016 is an important issue for the management of future epidemics and modeling work. since the zika virus has not yet been circulated in the lesser antilles, the cumulative incidence rate can be estimated by conducting a general population seroprevalence survey at the end of the epidemic, or more simply within a cohort of patients regularly monitored and whose habitat is distributed throughout the study area. thus, hiv-infected patients who benefit from regular clinical biological monitoring constitute a population sample perfectly adapted to the study of the emergence of the zika virus in the french west indies. the cumulative incidence of infection with the chikungunya virus after the 2014 epidemic has thus been estimated at 58% for martinique and guadeloupe using this method.

Eligibility criteria:
inclusion criteria: * adult (\> 18 years pold) * followed for hiv infection at the 2 investigators centers (1 located at martinique and 1 at guadeloupe) * resident in martinique /guadeloupe (french west indies) betwwen 01jan2016 and 31dec2016 * affiliate or beneficiary of a social security scheme. * informed consent signed by the patient exclusion criteria: * patient who has stayed in another area at risk of transmission of the zika virus
biomarker of acute exacerbation of copd

Conditions: COPD Exacerbation

Summary: acute exacerbation of chronic obstructive pulmonary disease (aecopd) is the main factor that leads to the deterioration of the disease. currently, the diagnosis of aecopd mainly relies on clinical manifestations, and good predictors or biomarkers are lacking. this study aims to explain the gene expression changes related to the disease at the transcriptional level and validate it in multiple levels, reveal specific biomarkers and potential pathogenesis, to provide a research basis for the diagnosis and treatment of aecopd.


Eligibility criteria:
for stable copd: inclusion criteria: 1. over 40 years old. 2. in line with the diagnostic criteria in gold 2018. 3. with the ability to sign informed consent. 4. can be followed up according to the study protocol. exclusion criteria: 1. with other pulmonary diseases (such as lung cancer, sarcoidosis, tuberculosis, pulmonary fibrosis, cystic fibrosis) and severe α1-antitrypsin deficiency. 2. with other inflammatory diseases (such as rheumatoid arthritis and inflammatory bowel disease, etc.). 3. a history of pulmonary surgery, or a diagnosis of malignant tumor recently. 4. a history of blood transfusion in 4 weeks. 5. participating in a double-blind drug clinical trial. 6. unable to walk. 7. using oral or intravenous steroid therapy. 8. with acute exacerbation in 4 weeks. for aecopd: inclusion criteria: patients who were over 40 years old were eligible for inclusion if they had a diagnosis of copd in their primary care clinical record and were presenting with an acute exacerbation of respiratory symptoms. exclusion criteria: 1. other specific diseases that may account for sudden changes in respiratory symptoms should be excluded by clinical or laboratory tests. 2. the remaining exclusion criteria were consistent with the above five criteria in stable copd. the control group: inclusion criteria: healthy people over 40 years old. exclusion criteria: with chronic airway diseases and other lung diseases, and heart, kidney, liver, and other important organ diseases.

Keywords: chronic obstructive pulmonary disease acute exacerbation transcriptomic pathogenesis biomarkers
clinical evaluation of the serum free light chain analysis

Conditions: Multiple Myeloma

Summary: background: in patients with multiple myeloma there is a raised level of a protein, named m-protein. this m-protein is normally used to monitor disease status and evaluate response to treatment, as a decrease in m-protein is taken as evidence of therapeutic efficacy. however, the m-protein has a long half life in serum, approximately three weeks, which tend to be a practical problem, since the investigators can first determine hereafter if the treatment is effective. a new assay has the possibility only to measure part of this protein, namely "the light chains", which also is measured in a blood sample. the half life of these light chains is much shorter, namely 2-6 hours. in theory, this means a more rapid measure of the effect of a given treatment, thereby being able to determine earlier if the treatment should continue or changed to another strategy. purpose: the purpose of this study is to evaluate the clinical value of the use of the serum free light chain (sflc) assay in comparison to the m-protein in monitoring patients under treatment for multiple myeloma. method: the investigators measure sflc in patients receiving there 1st treatment, either at the time of diagnosis or in the relapse setting. sflc is measured on a regular basis, and the results are compared to the m-protein.


Eligibility criteria:
inclusion criteria: * diagnosis of multiple myeloma * abnormal serum free light chains * medical needs of anti-myeloma therapy * receiving standard anti-myeloma therapy exclusion criteria: * dialysis * normal serum free light chains * dementia

Keywords: multiple myeloma free light chains
nurse-led smoking cessation with further follow-up in lifestyle centres - a randomized pilot study

Conditions: Smoking Cessation; Smoking Behaviors; Nurse's Role; Cardiovascular Diseases

Summary: the purpose of this randomized controlled pilot study is to test whether an in-hospital nurse-led smoking cessation intervention increases the refferal rate to healty life-centers in the municipalities. we will also describe the proportion who succeed in quitting smoking between the intervention group and the control group and obtain new knowledge about the patient and system factors of importance for participation to healty life-centers and for successful and unsuccessful smoking cessation.


Eligibility criteria:
inclusion criteria (all): * age\> 18 years and smokes at least 1 cigarette daily * hospitalized with a cardiovascular event (i.e. myocardial infarction, heart failure, unstable or stable angina, achyarrhythmias, bradyarrhythmias, carotid stenosis or claudication with need for peripheral revascularization) * sign informed consent and is expected to participate according to ich / gcp exclusion criteria (none of these): * does not meet the criteria to participate in the pilot project, i.e. patients who do not usually live or work in the vestre viken catchment area * chronic renal failure stage 4 or known allergic reaction to varenicline . any condition (e.g. psychosis, alcohol abuse, dementia) or situation that may pose a significant risk to the participant, confuse the results or make participation unethical * lack of norwegian and english knowledge * short life expectancy (\<12 months)
evaluation of the use of radiomics in 18f-fdopa pet examinations for the characterization of gliomas

Conditions: Study on the Use of Radiomics in Gliomas of Initial Disgnosis

Summary: the evaluation of gliomas in imaging represents a real challenge today, at the initial diagnosis, for therapeutic planning or follow-up treatment of these lesions. there is an urgent need for non-invasive imaging tools to evaluate a glioma throughout its management. at present, the diagnosis of certainty is only obtained through an anatomo-pathological analysis with sampling during an invasive procedure (surgery or biopsy). magnetic resonance imaging, through perfusion, diffusion imaging or spectroscopy is developing in gliomas. however, it remains time-consuming and is not always available. at the same time, positron emission tomography (pet) with amino acids is an interesting alternative for these brain tumours. amino acid pet has the advantage of being more specific than the abnormalities detected in mri and the amino acid radiotracers cross the blood-brain barrier, even if not broken, unlike gadolinium in mri. among these radiotracers, 18f-fdopa can, among other things, assist in the non-invasive staging of gliomas at initial diagnosis.


Eligibility criteria:
inclusion criteria: * patient having performed a pet/ct examination at 18f-fdopa for his glioma in the nuclear medicine department of the chru de brabois for which the raw data are available; * person who received full information on the organization of the research and did not object to the use of these data; * patients affiliated to a social security scheme exclusion criteria: * - person who received full information on the organization of the research and who objected to the use of the data * adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice). * a person of full age who is unable to give consent and who is not subject to a legal protection measure.

Keywords: 18f-fdopa glioma radiomics
effect of intradialytic exercise on erectile dysfunction in hemodialysis men

Conditions: Erectile Dysfunction

Summary: this study aimed to assess the effect of idep on ed and its associated psychological burden in hd men. forty hd men with ed were randomly assigned into the idep group (this group contained 20 hd men with ed who received intradialytic cycling three times per week) and the control group (this group served as waitlist men). outcomes : five-item international index of erectile function (fi-iief), ten-question rosenberg self-esteem scale (tq-rses), version three of the revised ucla loneliness scale (ls), the revised version of impact of event scale (rv-ies), beck's depression inventory (bdi), and state-trait anxiety inventory (s-tai) were assessed before and after 12 weeks.

this study aimed to assess the effect of idep on ed and its associated psychological burden in hd men. forty hd men with ed were randomly assigned into the idep group (this group contained 20 hd men with ed who received intradialytic cycling three times per week) and the control group (this group served as waitlist men). outcomes :five-item international index of erectile function (fi-iief), ten-question rosenberg self-esteem scale (tq-rses), version three of the revised ucla loneliness scale (ls), the revised version of impact of event scale (rv-ies), beck's depression inventory (bdi), and state-trait anxiety inventory (s-tai) were assessed before and after 12 weeks.

Eligibility criteria:
inclusion criteria: * men gender * hemodialysis for at least 6 months their * age between 35 to 48 years old. * married patient * education level. * the problem of ed was diagnosed by a physician at least 6 months before enrollment in this study. exclusion criteria: * prostatic disorders * systemic diseases (diabetes mellitus or hypertension) * cardiac diseases * musculoskeletal issues (e.g. muscle contusion, osteoarthritis, osteoporosis, osteopenia, etc.), * persistent hyperkalemia * penile shaft problems/implants * malignancies, acute/chronic infection or inflammation * autoimmune disease * cerebrovascular accidents/insults * a history of frequent hypoglycaemic episodes, * absolute contraindications to cardiopulmonary training/exertion * respiratory or liver diseases * participation in another structured interdialytic or intradialytic exercise programs * neurological diseases * consumptions of ed pharmacotherapies * previous pelvic surgeries * radiotherapy * low levels of testosterone or sex hormones, * psychological diseases * present history of smoking or alcohol consumption.
utilisation of telemedicine in optimal cardiac rehabilitation program in patients after myocardial revascularization

Conditions: Coronary Artery Disease With Myocardial Infarction

Summary: although clinical data demonstrate advantages of combining complete revascularization with optimal cardiac rehabilitation (cr) less than one-third of patients in european countries participate in cardiac rehabilitation programs. therefore, in cooperation with polish leaders in cardiovascular medicine, rehabilitation and medical software design we aim to introduce and evaluate the system of optimal cardiac telerehabilitation in addition to optimal treatment of coronary artery disease.

although clinical data demonstrate advantages of combining complete revascularization with optimal cardiac rehabilitation (ocr) less than one-third of patients in european countries participate in cardiac rehabilitation programs. in addition, the major limitations of current cr programs are their short duration without long-term follow-up, lack of appropriate clinical and functional monitoring, and structural problems including geographic misdistribution of available programs. therefore, in cooperation with polish leaders in cardiovascular medicine, rehabilitation and medical software design we aim to introduce and evaluate the system of optimal cardiac telerehabilitation in addition to optimal treatment of coronary artery disease. primarily, the telerehabilitation system will be designed and developed. secondly, coordinating center will be build and technical tests will be performed in order to evaluate its integrity with telerehabilitation system. thirdly, the whole system will be validated in clinical settings on patients' population with coronary artery disease and completed revascularization. finally, procedural steps will be executed in order to prepare the whole system of optimal cardiac telerehabilitation for implementation.

Eligibility criteria:
inclusion criteria: * age over 18 and below 70 * completed revascularization in patients with stable or unstable angina or after myocardial infarction without st-segment elevation (nstemi) * in patients with suspected myocardial scars, mri will be recommended to confirm myocardial viability. * eligibility to participate in a program of early cardiac rehabilitation * signed informed consent form * the ability to use telerehabilitation system exclusion criteria: * acute myocardial infarction with st segment elevation/new onset of left bundle branch block (lbbb), * suboptimal (not completed) revascularisation * ejection fraction \<40%. * acute heart failure (killip iv) at the time of admission to the hospital * dual antiplatelet therapy can not be maintained for 1 year after pci * haemorrhagic stroke in the past * ischemic stroke or transient ischemia in previous 6 weeks * platelet count \<100,000 / mm3 * chronic renal failure with creatinine clearance \<30ml / min / 1.73m2 * planned surgery * pregnancy or planned pregnancies * expected life expectancy less than 3 years after enrollment

Keywords: cardiac tele-rehabilitation, myocardial revascularization
study in toddlers (12-18 months) comparing a booster dose of vaxem hib and hiberix vaccines for the prevention of haemophilus influenzae type b infections in china

Conditions: Haemophilus Influenzae Type b (Hib) Infection

Summary: this study will evaluate the safety and immunogenicity of booster doses of the two vaccines used to prevent haemophilus influenzae type b infections in children 12-18 months of age.


Eligibility criteria:
inclusion criteria: * toddlers 12-18 months of age who have previously participated in study m37p2. exclusion criteria: * prior hib booster administration. * history of serious reaction(s) following vaccination. * vaccination within 14 days of study vaccination. * known or suspected immune impairment. * for additional entry criteria please refer to the protocol.

Keywords: haemophilus influenzae type b (hib) vaccine booster
clinical efficacy of combination therapy based on high-dose biapenem in crkp infections

Conditions: High-dose Biapenem

Summary: carbapenem resistance is a high mortality rate of klebsiella pneumoniae infection. it has been proved that high-dose carbapenem can reduce mortality and has a certain clinical effect. in this study, a high dose of biapenem was compared to determine whether it had a similar effect than meropenem.


Eligibility criteria:
inclusion criteria: * icu hospitalized for more than 3 days; * biapenem used for more than 3 days exclusion criteria: * patients who refuse to be included in the group or pregnant women or under the age of 14 or icu hospitalized for less than 3 days

Keywords: high-dose biapenem carbapenem resistance klebsiella pneumoniae clinical efficacy
rasburicase for the treatment/prevention of hyperuricemia in adult patients with relapsing aggressive non hodgkin's lymphoma

Conditions: Hyperuricemia

Summary: the primary objective was to evaluate the efficacy of rasburicase in terms of prevention and treatment of hyperuricemia related to tumor lysis syndrome (tls) in 2 populations of adult patients, previously treated or not with urate oxidase, with relapsing aggressive non-hodgkin's lymphoma (nhl) and at risk of tls, presenting with hyperuricemia and/or bulky disease at diagnostic of relapse. the secondary objectives were to : * evaluate the efficacy of rasburicase in terms of renal protection, * evaluate the safety of rasburicase in the two cohorts of patients, * correlate efficacy and safety results with antibodies generation/level.


Eligibility criteria:
patients with histologically proven aggressive non hodgkin's lymphoma
early subcutaneous insulin glargine plus standard of care for treatment of diabetic ketoacidosis

Conditions: Diabetic Ketoacidosis

Summary: the purpose of this study is to determine whether adult dka patients who present to the emergency department treated with early subcutaneous long acting insulin versus standard care receive a shorter total duration of intravenous (iv) insulin infusion.

specific aims: to evaluate the impact of early administration of subcutaneous glargine versus standard care on time of insulin infusion in dka patients and other secondary outcomes listed in this application. methods: dka patients enrolled in this study will receive the long acting glargine dose (0.3 units/kg with a maximum dose of 30 units) within two hours after initiation the iv insulin infusion. besides timing of the glargine dose, no other changes in standard patient care will occur in those patients enrolled in this study, the same labs will be collected and the insulin infusion will be titrated using the same hospital protocol algorithm. patients enrolled in the prospective arm will be compared with the retrospective control group, which received standard insulin therapy (subcutaneous insulin glargine administered at least 2 to 3 hours prior to termination of the insulin infusion). there will be 18 patients in this group selected in reverse chronological order from our pre-specified date range of 8/1/2014 to 7/31/2016.

Eligibility criteria:
inclusion criteria: * bicarbonate \<18 mg/dl * anion gap \>16 * blood glucose \>250 mg/dl * ketonemia or ketonuria exclusion criteria: * pregnant women * refused consent * patient left ed against medical advice

Keywords: emergency department insulin adult
prontosan versus saline in the cleansing of chronic leg ulcers in diabetic patients

Conditions: Diabetic Complications

Summary: this is a randomized controlled double blinded study involving two (2) investigational sites in the united states. all subjects (n=40) will receive either prontosan wound irrigation solution and gel treatment or standard of care treatment (0.9% saline) and placebo gel. this is a 12-week study.


Eligibility criteria:
inclusion criteria: * male or female diabetic (type i or ii) patients ≥ 18 years of age. * diabetic ulcer(s) present for ≥ 4 weeks located below the knee. * a total surface area of ≥ 3 cm2 and ≤ 16 cm2. * willingness to wear an off-loading device if medically indicated (e.g., dh shoe or walker). exclusion criteria: * pregnant women and nursing mothers. * uncontrolled diabetes as defined by glucose levels \>225 mg/dl. * hba1c ≥ 12%. * subjects with a wound infection. * subjects receiving antibiotic therapy within 14 days of enrollment. * subject with history of or clinical evidence of: cardiac insufficiency (nyha functional classification iv), angina pectoris (ccs functional classification iv), unstable pulmonary, renal, hepatic, endocrine or hematologic disease as determined by the investigator (serum creatinine of \> 3.0; transaminase or alkaline phosphatase levels equal to or greater than 5 times the upper limit) malnutrition (albumin \< 2.5 g/dl). * peripheral arterial occlusive disease with a non-palpable pulse on both dorsal pedial and the posterior tibial artery. * presence of gangrene. * active rheumatic or collagen vascular disease (including rheumatoid arthritis, scleroderma, and systemic lupus erythematosus) * subjects that have been diagnosed with hbv, hvc, aids or are hiv positive. * osteomyelitis diagnosed by x-ray, bone biopsy, or other radiological procedure within 90 days prior to screening period. * active radiation therapy below the hip. * subject currently receiving, or has received oral or parenteral corticosteroids, immunosuppressive or cytotoxic agents within 30 days prior to baseline visit (visit 1, week 0) or is anticipated to require such agents during the course of the study. * current participation or participation in another investigational drug or medical device study within the last 30 days. * subjects who test positive for alcohol and or illicit drug use. * subjects who are unable to comprehend or comply with study requirements or ability to sign an informed consent. * subjects, who in the opinion of the investigator would not be a suitable candidate for this study (reason for exclusion needs to be documented).

Keywords: cleansing chronic leg ulcers diabetic patients
biomarkers in tissue and blood samples from patients with early-stage non-small cell lung cancer

Conditions: Lung Cancer

Summary: rationale: studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. purpose: this research study is studying biomarkers in tissue and blood samples from patients with early-stage non-small cell lung cancer.

objectives: * evaluate aberrant methylation patterns in tissue and serum samples from patients with early-stage non-small cell lung cancer (nsclc) to validate the johns hopkins single institutional study. * attempt to define subgroups of patients at greater risk for recurrent or metastatic disease who may benefit from more aggressive adjuvant therapeutic regimens. * develop prognostic indicators for disease-specific and overall survival. * define new potential molecular targets for therapy. outline: archived tumor and intrathoracic lymph node tissue samples are analyzed for aberrant dna methylation (p16/cdkn2a, dap kinase, h-cadherin, apc, and rassf1a) by methylation-specific pcr. analyses are then compared with the preliminary data from the johns hopkins institutional study.

Eligibility criteria:
disease characteristics: * diagnosis of early-stage non-small cell lung cancer * t1 or t2, n0 disease * had a lobectomy or greater resection with negative surgical margins (r0 resection) * available tumor and lymph node specimens from patients enrolled on acosog-z0040 and acosog-z0030 trials * node-negative with recurrent disease within 3 years (cases) * node-negative patients without recurrent disease (controls) prior concurrent therapy: * see disease characteristics

Keywords: recurrent non-small cell lung cancer stage i non-small cell lung cancer stage ii non-small cell lung cancer squamous cell lung cancer